Press Releases

Some content here depending on data type

01/12/2015

Athens, November 30th 2015

   The successful business course of the Greek pharmaceutical company DEMO SA stands out as well as it is acknowledged. The company received two major awards for its business course and prospects. Specifically, on Thursday 26/11, Mr. Dimitris Demos, DEMOS’s Vice President and CEO, was awarded with the“KOUROS” Prize for his performance in the International Economic Arena by the Entrepreneurship Club.

_

   Moreover, once again DEMO was distinguished at the Annual Meeting of Business Excellence, “Salus Index 2015”, which took place a day before, on Wednesday 25/11. On behalf of DEMO, Mr. Aristomenis Vassilopoulos, DEMO’s Sales Director, received the award.

_

   Both of these distinctions constitute a significant acknowledgment for DEMO, which shows annual growth rate over 22% the last eight years as well as turnover of €125 today (from €112 million in 2014) noting an outstanding increase of

Posted in Demo's News
01/12/2015

   Athens, November 11th 2015 – DEMO SA , which supports our country’s culture and young people’s contact with the global works of art, is the key sponsor of the Exhibition “Pablo Picasso-Jean Cocteau, the Modernist Innovators, from the Pablo Picasso Münster Museum and the Collection of Giannis Kontaxopoulos”. The exhibition, which opened its doors for the public on November 4th, is hosted by the Foundation for the Fine Arts & Music B & M Theocharakis.

_

   Being consistent with its philosophy of active social presence and participation, DEMO S.A. is present at important cultural events as well. It supports a highly remarkable cultural proposal that comprises of the artwork of two leading artists that have influenced significantly the history of art. Demo’s sponsorship is incorporated into the overall 2015-2016 Corporate Social Responsibility program that focuses on the Human.

_

   An exceptionally interesting selection of 190 works of painting, engraving, pottery and artistic publications of the two

Posted in Demo's News
15/09/2015

   Athens, September 15th 2015 – It was fifty years ago when Stavros Demos opened a pharmacy, which has evolved into the biggest pharmaceutical company in the domestic hospital market and one of the most significant companies at a global level, DEMO. The company celebrated its 50 years of successful and upward course along with its employees at an event with an emotional atmosphere full of hope and optimism for the future.

_

   DEMO S.A. is the most significant Greek exporter of pharmaceutical products the last decade, with an extensive sales network in Europe, Asia, Africa, Oceania and Middle East. Since the end of 2013, the company has expanded in Germany with the subsidiary DEMO Pharmaceuticals GmbH based in Munich; it has also started operating a branch in China, while the operation of seven more branches in other countries is the company’s primary goal for the future. Moreover, the company has managed to be steadily in the first place of the domestic hospital market since 2000.

_

   The steady growth of DEMO S.A. is the result of a series of investments, such as the creation of the larg

Posted in Demo's News
15/02/2014

DEMO S.A is certified member of the internationally recognized organization TRACE, which works together with companies to promote and ensure transparency in corporate practices through the implementation of anti- bribery standards. _ _ _

Posted in Demo's News
04/05/2010

   DEMO Pharmaceutical Industry S.A. today announced the pan-european registration of its Teicoplanin injection product (Talinac) is proceeding as planned.

_

_

_

Posted in Demo's News
03/08/2009

   DEMO S.A. today announced the inauguration of its brand new production facility for carbapenems. The new facility has been designed in accordance with the most stringent regulations set forth by the US Food & Drug Authority (US/FDA) and is the only in Greece and among the very few in Europe.

_

   The new facility covers a total area of 2,000 sq.m. with a manufacturing capacity that exceeds 30,000,000 vials annually.

_

   For more information please contact us at info@demo.gr   _ _ _

Posted in Demo's News
20/03/2009

   DEMO Pharmaceutical Industry S.A. today was informed by the UK regulatory authorities that its pan-european registration of its Meropenem injection product (Merozan) in six of the biggest markets in Europe has reached its Day 105.  It is expected that Merozan will be launched in Europe during the frst quarter of 2010.

_

_

_

Posted in Demo's News